Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Levetiracetam is an antiepileptic that displays distinctive properties from conventional antiepileptic drugs. Displays potent seizure protection in animal models of chronic epilepsy but lacks activity in acute seizure models. Binds synaptic vesicle protein 2A (SV2A) and inhibits Na+-dependent Cl-/HCO3- exchange. In a mouse model of Alzheimer's disease, Levetiracetam rescues levels of presynaptic vesicle fusion and neurotransmitter release, reduces Aβ42 and APP levels and decreases deposits of amyloid plaque; in vitro Levetiracetam inhibits Aβ-induced glutamate from astrocytes.
Levetiracetam is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 170.21. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.88 mL||29.38 mL||58.75 mL|
|5 mM||1.18 mL||5.88 mL||11.75 mL|
|10 mM||0.59 mL||2.94 mL||5.88 mL|
|50 mM||0.12 mL||0.59 mL||1.18 mL|
References are publications that support the biological activity of the product.
Smedt et al (2007) LeveT: the profile of a novel anticonvulsant drug - part I: preclinical data. CNS Drug Rev. 13 43 PMID: 17461889
Ueda et al (2007) Effect of LeveT on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection. Brain Res. 1151 55 PMID: 17408599
Lynch et al (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug LeveT. Proct.Natl.Acad.Sci. USA 101 9861 PMID: 15210974
Sanchez et al (2012) Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc.Natl.Acad.Sci. USA 109 E2895 PMID: 22869752
Sanz-Blasco et al (2016) Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes. Neuroreport 27 705 PMID: 27183239
Rao and Savas (2021) Levetiracetam treatment normalizes levels of presynaptic endocytosis machinery and restores nonamyloidogenic APP processing in App knock-in mice J.Proteome Res. 20 3580 PMID: 34106705
If you know of a relevant reference for Levetiracetam, please let us know.
Keywords: Levetiracetam, Levetiracetam supplier, Anti-epileptic, binds, SV2A, Exocytosis, Endocytosis, Protein, Translocation, UCBL059, Alzheimers, APP, amyloid, precursor, protein, Ab, Abeta, Aβ, Keppra, UCB, L059, 2839, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Levetiracetam. Do you know of a great paper that uses Levetiracetam from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Levetiracetam and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image